Incidence

Global Cell Dissociation Market Analysis 2023-2028: Non-Enzymatic Tissue Dissociation - A Lucrative Market Opportunity - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023

This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.

Key Points: 
  • This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.
  • The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total cell dissociation market.
  • Based on product, the cell dissociation market is segmented into enzymatic dissociation agents, non-enzymatic dissociation agents, and instruments & accessories.
  • Based on tissue type, the cell dissociation market has been segmented into connective tissue, epithelial tissue, and other tissues (muscle tissue, lung tissue, and nerve tissue).

I’ve spent 50 years studying one seabird colony fight its way back from near extinction – now it faces new threats

Retrieved on: 
Monday, July 31, 2023

But by the end of the second world war, this number had plummeted by about 95% and continued to decline for the next few decades.

Key Points: 
  • But by the end of the second world war, this number had plummeted by about 95% and continued to decline for the next few decades.
  • In 1967, for example, the supertanker SS Torrey Canyon spilled over 100,000 tonnes of crude oil into the English channel.
  • This resurgence has been the subject of a long-term study conducted by myself and my colleagues over past 50 years.

Guillemots on the rise

    • We have been monitoring the survival and breeding success of guillemots on Skomer.
    • Our aim was to establish whether chick production, breeding age and adult and chick survival rates could explain the observed increase in their numbers.
    • In the 1970s, around 90% of the dead guillemots found on beaches surrounding the North Sea were contaminated with oil.

Breeding earlier

    • One of our most striking results is that the timing of guillemot breeding has advanced by more than two weeks on average since the 1970s.
    • We believe the early breeding season might be linked to the seasonal availability of their fish prey.

Dealing with extreme weather

    • Sustained bad winter weather makes it difficult for guillemots and puffins (another member of the bird family known as auks) to find food.
    • In early 2014, a series of storms resulted in the deaths of over 55,000 seabirds around European coastlines, including 15,000 guillemots.
    • More worrying is the increasing incidence of extreme weather during the guillemots’ breeding season.
    • Summers are witnessing stronger winds, rougher seas, torrential rain and extreme heat – all of which can reduce guillemot breeding success.

Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder

Retrieved on: 
Monday, July 31, 2023

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age.
  • ZTALMY may be continued in patients 18 years of age and older.
  • In the Marigold open label extension study, patients treated with ZTALMY for at least 12 months (n=48) experienced a median 49.6% reduction in major motor seizure frequency.
  • In July 2021, Marinus and Orion Corporation entered into a collaboration agreement which grants Orion the right to commercialize ZTALMY in Europe.

First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal

Retrieved on: 
Friday, July 28, 2023

While Syfovre’s efficacy is perceived as marginal, it still provided some hope to patients that previously had none.

Key Points: 
  • While Syfovre’s efficacy is perceived as marginal, it still provided some hope to patients that previously had none.
  • According to the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee, ophthalmologists have reported cases of intraocular inflammation (IOI) following the administration of Syfovre.
  • Of particular note is the damage from the Syfovre post-marketing safety signal may expand beyond Apellis and Syfovre itself.
  • Launch Dynamix™ coverage (for Syfovre and pending for ACP) consists of 18 monthly pulses and six quarterly deep dives (including qualitative interviews with ophthalmologists).

Minimally Invasive Procedures and Growing Geriatric Population Fuel Global Aneurysm Clips Market Growth: Aesculap, Integra LifeSciences, and Galvani Bioelectronics Among Key Players

Retrieved on: 
Friday, July 28, 2023

The global aneurysm clips market size is anticipated to reach USD 112.92 million by 2030, expanding at a CAGR of 7.36% from 2023 to 2030.

Key Points: 
  • The global aneurysm clips market size is anticipated to reach USD 112.92 million by 2030, expanding at a CAGR of 7.36% from 2023 to 2030.
  • The market is expected to grow due to the rising incidence of intracranial aneurysms, the rising adoption of minimally invasive intracranial aneurysms procedures, and the rise in the geriatric population.
  • The adoption of surgical clips both in laparoscopic procedures as well as open surgeries is anticipated to fuel the demand for aneurysm clips in the upcoming years.
  • Minimized incision size during the procedures and the duration of speedy recovery are the major factors driving the use of aneurysm clips among surgeons.

Anticipated Surge in Global Gene Panel Market: Fuelled by Rising Prevalence of Genetic Disorders – ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023

The global gene panel market is poised for impressive growth during the forecast period, driven by the increasing prevalence of genetic disorders such as Down syndrome, sickle cell disease, Tay-Sachs disease, and others.

Key Points: 
  • The global gene panel market is poised for impressive growth during the forecast period, driven by the increasing prevalence of genetic disorders such as Down syndrome, sickle cell disease, Tay-Sachs disease, and others.
  • The demand for gene panel testing surges in response to the increasing disorders caused by genetic mutations.
  • Genetic disorders are currently prevalent in the geriatric population, significantly supporting the expansion of the gene panel market.
  • The United States leads the global gene panel market due to the growing demand for gene panel techniques in response to the rising cancer cases worldwide.

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Retrieved on: 
Friday, July 28, 2023

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Key Points: 
  • SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
  • The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University.
  • Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
  • Samuel P. Chapman, Director of Parents for Safer Children, stated, “Prescription strength ZIMHI is the best remedy available for opioid overdose.

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Retrieved on: 
Friday, July 28, 2023

SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II investigator-initiated trial of eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with radiotherapy and the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for patients with soft tissue sarcoma. This chemo-free trial is the first to evaluate efti in a neoadjuvant setting.

Key Points: 
  • This chemo-free trial is the first to evaluate efti in a neoadjuvant setting.
  • Soft tissue sarcoma (STS), an orphan disease, represents a high unmet medical need with a poor prognosis.
  • The trial’s Principal Investigators are Dr. Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO.
  • New information arising from this innovative trial may further broaden the future clinical development of efti and, in the end, bring even greater benefit to patients.”

Kemper Announces Schedule for Second Quarter 2023 Earnings Release and Preliminary Results

Retrieved on: 
Thursday, July 27, 2023

Combined ratios for the second quarter were adversely impacted by prior year claim reserve additions and current year catastrophes.

Key Points: 
  • Combined ratios for the second quarter were adversely impacted by prior year claim reserve additions and current year catastrophes.
  • Preliminary pre-tax current year catastrophe losses for the second quarter were approximately $39 million with the following attribution:
    Life & Health after-tax income for the quarter was approximately $9 million.
  • There were no applicable significant non-recurring items that Kemper excluded from the calculation of Adjusted Consolidated Net Operating Loss for the three months ended June 30, 2023.
  • Kemper will host its conference call to discuss second quarter 2023 results on Monday, August 7, 2023, at 5:00 pm Eastern (4:00 pm Central).

DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics's Platform

Retrieved on: 
Thursday, July 27, 2023

Now, for the first time, researchers have achieved genome-wide detection of tumor-specific mutations from the same low-coverage whole genome sequencing methods that form the basis of the DELFI Diagnostics platform.

Key Points: 
  • Now, for the first time, researchers have achieved genome-wide detection of tumor-specific mutations from the same low-coverage whole genome sequencing methods that form the basis of the DELFI Diagnostics platform.
  • The combined technology also showed high performance in other applications including monitoring response to therapy, and distinguishing small-cell lung cancer from non-small cell lung cancer.
  • "We founded DELFI Diagnostics to address population-health needs in cancer detection with low-cost, flexibly deployable technology," said Nicholas Dracopoli, PhD, DELFI Diagnostics's Chief Scientific Officer and Co-Founder.
  • "We have already shown that this platform can detect lung cancer with very high sensitivity," said Peter Bach, MD, DELFI Diagnostics's Chief Medical Officer.